Nasopharyngeal carcinoma (NPC) is a common head and neck malignancy. The incidence of NPC is higher in Southern China and Southeast Asia compared with Western countries. Given its high radiosensitivity, the standard treatment for NPC is radiotherapy. However, radioresistance remains a serious obstacle to successful treatment. Radioresistance can cause local recurrence and distant metastases in some patients after treatment by radiation. Thus, special emphasis has been given to the discovery of effective radiosensitizers. This review aims to discuss the biomarkers, classified according to the main mechanisms of radiosensitization, which can enhance the sensitivity of NPC cells to ionizing radiation.
Introduction
Nasopharyngeal carcinoma (NPC) is a highly metastatic cancer that originates from the epithelial lining of the nasopharynx. NPC occurs mostly in the pharyngeal recess (fossa of Rosenmüller) and the eustachian tube opening in the nasopharynx 1 . Compared with other head and neck malignancies, NPC is unique in the aspects of epidemiology, pathology, and clinical manifestation. The etiology involves various factors, including genetic susceptibility, Epstein-Barr virus (EBV) infection, and exposure to chemical carcinogens [1] [2] [3] . According to the histological classification of World Health Organization, NPC is divided into three types: keratinizing squamous cell carcinoma (type I), non-keratinizing squamous cell carcinoma (type II), and undifferentiated carcinomas (type III) 1 . In comparison with the differentiated NPC, undifferentiated NPC is more aggressive, with a higher incidence of distant metastasis 4 .
NPC exhibits a remarkable geographic distribution that the incidence in southern parts of China and Southeast Asia, usually belonging to types II and III, is higher than that in Western countries. In the West, NPC occurs sporadically and usually belongs to type I 1 . Distinguished by its unique clinical and pathologic characteristics, NPC is highly radiosensitive. Compared with type I, types II and III have a higher response rate to ionizing radiation 4 . Thus, radiotherapy serves as a standard treatment that is effective to control the early tumor with good prognosis, achieving a 5-year overall survival of 90% and 84% for early stage I and IIA disease, respectively 5 . However, along with radiotherapy, radioresistance also exists in many cases. Moreover, radioresistance can cause locoregional recurrence and distant metastasis after radiotherapy in some patients, especially when the tumor is in the advanced stage (stage III or IV) 6 . Therefore, for the relatively advanced stage, combined radio-chemotherapy may increase survival rate, which is 50%-70% as reported 6 . However, radioresistance still exists in these cases. Along with the damage of radiation to normal tissues, radioresistance remains a serious obstacle to successful treatment. Hence, methods of decreasing NPC radioresistance and enhancing radiosensitivity are urgently needed. In this context, special emphasis is given to the exploitation of effective radiosensitizers according to the three main categories of radiosensitization mechanisms 7 .
Previous studies showed that in response to DNA damage, the ataxia telangiectasia mutated (ATM) kinase catalyzes the phosphorylation of histone variant H2AX to recognize and marks the sites of damaged DNA 9 . NFBD1 then recruits repair factors including MRE11, RAD50, and NBS1 complex to the marked sites to form a nuclear foci, thus contributing to an increase in the fidelity of genomic integrity 8 . Furthermore, Lou et al. 10 found that the depletion of endogenous NFBD1 can cause a complete loss of nuclear foci formation and induce genomic instability and DNA repair defects. This finding demonstrates that NFBD1 has a close relationship with the initiation and promotion of DNA repair process. In vivo, the generation of MDC1 knockout mice had the characteristics of growth retardation, male infertility, defective class switching, and increased radiation sensitivity 10 . The expression level of NFBD1 in NPC cells was absolutely high, and the suppression of NFBD1 could increase the rate of apoptosis of NPC cells and the sensitivity to chemotherapy 11, 12 . Recently, Wang et al. 13 demonstrates that Lentivirus-mediated shRNA targeting NFBD1 can steadily silence the expression of NFBD1 gene and enhance the radiosensitivity of CNE-1 cells. These results may eventually contribute to the clinical investigation of prediction markers and prognostic factors, as well to the development of radiosensitizing molecules for therapeutic use.
Cell cycle redistribution
Radiosensitivity of the cells varies according to their positions in the cell cycle. Cells in G 2 /M are approximately 3-fold more sensitive to radiation than cells in late S-phase/early G 1 , but the exact cause of variation is currently not completely known 14 .
Thus, agents that can block the progression of a cell cycle in a radiosensitive phase may induce significant radiosensitization.
COX-2
Cyclooxygenase or prostaglandin endoperoxidase synthase (COX) is an enzyme that participates in the formation of prostaglandins (PGs) and is also recognized as an important chemical mediator for inflammation. COX has two isoforms: COX-1 and COX-2. COX-2, not usually expressed in most normal tissues, has a close relationship with the synthesis of PGs in inflamed and neoplastic tissues 15 . COX-2 overexpression has been reported in most cancers, such as esophageal, gastric, pancreatic, colorectal, lung, and breast cancers [16] [17] [18] , suggesting that COX-2 overexpression has a close relationship with cancer progression 15 . Some preclinical studies have investigated the role of COX-2 in carcinogenesis 19 . In these studies, upregulation of COX-2 can regulate angiogenesis, resist apoptosis, and influence cell proliferation successfully through induction of vascular endothelial growth factor (VEGF) and translocation of HIF-1α protein, increase of the expression of proapoptotic Bcl-2 proteins, inhibition of cytochrome c released from mitochondria, and control of G 1 and S phase cyclins 20 . Thus, the selective COX-2 inhibitors can be regarded as anticancer agents. Recently, a preclinical study showed that high COX-2 expression was found in more than 70% of NPC, and these tumors had earlier regional lymph node metastasis, distant metastasis, and poor responses to chemotherapy, as well as a lower 5-year survival rate compared with low COX-2 expression or negative tumors 21 . Meanwhile, an in vitro study demonstrated that adding the selective COX-2 inhibitor NS-398 in NPC cells could increase the radiationinduced cell death 22 . Furthermore, Sun et al. 23 showed that COX-2 overexpressing proteins in NPC cells have radioprotective effects, and silence of the expression of COX-2 can reduce radiation-induced damage repair, thereby enhancing cellular radiosensitivity; this finding lays a theoretical foundation on new gene-radiation combined therapy for NPC. The underlying mechanism may be attributable to the G 2 -M cell phase arrest and enhancement of cell apoptosis 24 .
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GnT-V
Protein glycosylation, a type of post-translational modification, is vital for the glycoprotein, which can affect cell growth, differentiation, and tumor metastasis 28 . The glycosyltransferase, located in the Golgi apparatus, plays an important role in protein glycosylation. The glycosyltransferase contains at least six Nacetylglucosaminyltransferases (GnTs), defined as GnT-I-VI. N-glycosyltransferase-V (GnT-V) is recognized as a primary member of the glycosyltransferase family, catalyzing the formation of β1, 6 GlcNAc branching structures. Many studies have shown that upregulation of the β1, 6 GlcNAc branched N-glycans structure is related to malignant transformation through various ways, such as inhibiting cell apoptosis and enhancing cell proliferation 29 . Previous studies have shown that GnT-V plays an important role in malignant tumors. Recently, Wei et al. 30 demonstrated that downregulation of
GnT-V inhibited NPC cell line CNE-2 clonogenic survival after radiation in vitro. Another study investigated the role of GnT-V on the radiosensitivity of NPC cells and its underlying mechanisms. These results showed that downregulation of GnT-V in NPC enhanced radiosensitivity in vitro and in vivo. The underlying mechanisms may be linked to the cell cycle G 2 -M arrest and the reduction of Bcl-2/Bax ratio. GnT-V may be a potential target for predicting NPC response to radiotherapy 31 .
Jab1/CSN5
C-Jun activation domain-binding protein-1 ( Jab1) is a modulator of intracellular signaling. Through its existence as the fifth component of the constitutive photomorphogenic-9 signalosome (CSN5), Jab1/CSN5 can regulate cellular proliferation and apoptosis by functionally deactivating some key negative regulatory proteins and tumor suppressors, such as p53 and p27 32 . In previous studies, overexpression of Jab1 was found to be correlated with poor prognosis in some tumor types, such as pancreatic adenocarcinomas 33 , breast cancers 34 , and NPC 35 .
Other previous studies had found that Jab1 played an important role in the pathologenesis and radioresistance in NPC 36 . Curcumin is a common chemopreventive agent. Although it plays an important role in anticancer activities in tumor cells 37 , many previous studies showed that curcumin was limited in its application in anticancer therapy because of its poor bioavailability, rapid metabolism, and instability under several physiologic conditions 38 . Thus, analogues of curcumin, which have increased anticancer activity and similar safety profiles as curcumin, have been developed in recent years 39, 40 . Pan et al. 41 used T83 (a new 4-arylidene curcumin analogue) to inhibit the expression of Jab1 in NPC cells, demonstrating that inhibition of Jab1 could reduce tumor cell growth, induce G 2 /M arrest, and increase tumor cell apoptosis, thus enhancing the sensitivities of NPC cells to radiotherapy. This study verified T83 as a potential targeted therapy, which may increase the radiosensitivities of NPC cells, providing a promising and effective treatment for NPC patients.
Increased initial damage
Through production of free radical species and direct ionization of target molecules, ionizing radiation can cause cellular damage. DNA is the standard target of ionizing radiation damage, and radiation induced double-strand DNA breaks are fatal. Although we do not completely know the exact type of radiation-induced damage, we can use the agents that could cause more initial damage to cellular targets to achieve an increasing cytotoxic effect of radiation.
DNA topoisomerase I
DNA topoisomerases, first discovered in 1971, are important enzymes that can regulate the transformation of DNA topological isomer. DNA topoisomerases have two types: DNA topoisomerase I and DNA topoisomerase II 42 . Topoisomerase I (Top I), which is ATP-independent, catalyzes the relaxation of superhelical DNA by cutting off a single chain, allowing the intact chain through the broken chain (Top IA) or leaving the broken chain free to rotate around the intact chain (Top IB). Topoisomerase II (Top II), which is ATP-dependent, mediates the generation of breaks in both chains of the DNA duplex 43 . Both topoisomerase I and II play important roles in many aspects of DNA metabolism, such as DNA replication and DNA transcription, especially the topoisomerase I, which is very essential for the maintenance of the genomic stability 42 .
Furthermore, drugs that interfere with topoisomerase I-mediated cleavage rejoining of DNA chains can be widely used in the treatment of cancer 44 . These drugs have also been regarded as effective radiosensitizers when used before radiotherapy, including derivatives of camptothecin 45 . Topotecan (TPT) is a derivative of camptothecin, which can inhibit topoisomerase I in S phase cells. TPT has been suggested to be effective in the radiotherapy of NPC. Zhang et al. 46 established a xenografted human NPC model in nude mice and investigated the synergistic effect of TPT and chronoradiotherapy. The results showed that TPT has a radiosensitizing effect on xenografted human NPC. More importantly, TPT has a circadian dependence, thus contributing to further optimization of therapeutic schedules for NPC. Moreover, the potential mechanism of chronomodulated radiosensitization of TPT may be related to the circadian rhythm of tumor hypoxia and the radiation reluctance of cells in S phase, causing G 2 /M phase arrest.
Nitric oxide synthases
NO is a gaseous molecule that has two types: enzymedependent NO and enzyme-independent NO. In human cells, NO is enzyme-dependent and comes from L-arginine catalyzed by NO synthases (NOS). NO plays a very important role in cell signaling pathway through cell-mediated immune responses, cytotoxicity, formation of guanylate cyclase, and cyclic guanosine monophosphate 47 . Previous studies showed that NO is a hypoxic cell radiosensitizer when combined with radiotherapy 48 . Recent evidence showed that NO is an initiator of apoptotic signals due to its ability to form peroxynitrite, which can activate oxidative stress-induced apoptosis 49 . Stimulated by cytokines, inducible NOS (iNOS) can produce much NO. Thus, increased iNOS is associated with increased apoptosis. To explore the function of iNOS in NPC, Jayasurya et al. 50 demonstrated that low iNOS expression comes with high incidence of tumor local recurrence and metastasis, probably because of decreased apoptosis. In addition, NPC cells with high iNOS expressions may be more sensitive to radiotherapy.
Others
The mechanisms of the following biomarkers do not belong to the three main categories or are not completely known right now.
EGFR and IGF-1R
EGFR and insulin-like growth factor-1 receptor (IGF-1R) are key members of the tyrosine kinase receptor family, whose ligands are respectively epidermal growth factor and insulin-like growth factor-1 (IGF-1). The combinations of both receptor and ligand are involved in the development of malignant tumor through modulation of tumor cell cycles, apoptosis, and interactions with the surrounding environment 51 . Moreover, IGF-1R plays a crucial role in the generation of drug resistance during anticancer therapy and also in the proliferation and transformation of tumor cells. Meanwhile, EGFR significantly contributes to promotion of cell proliferation 52 . Early experiments showed that combining short hairpin RNA segments to IGF-1 and EGFRs via plasmid or virus transfection could significantly inhibit NPC cell growth, induce apoptosis, and increase chemotherapy sensitivity in vitro 53 . Meanwhile, another study found that overexpression of EGFR and IGF-1R in advanced and recurrent NPC tissues affected the radiosensitivity of NPC cells 54 . Recently, Liu et al. 55 verified that the dual-silencing of IGF-1R and EGFR, which are capable to decrease the expression of NPC cyclins and to block cell cycles, may promote the radiosensitivities and apotosis of NPC cells.
VEGF
VEGF, earlier known as vascular permeability factor, is a specific heparin-binding growth factor of vascular endothelial cells that can induce angiogenesis to support the growth of both normal and tumor tissues in vivo. As it is very essential for the progressive enlargement of malignant tumor, the function of VEGF in cancer treatment has been widely studied. Some studies found that VEGF made a great contribution to radioresistance in cancer radiotherapy both in vitro and in vivo. Those results suggested that targeting VEGF may inhibit cancer cell growth, decrease radioresistance, and prevent metastasis 56 .
Angiotensin II (Ang II) is an important part of the reninangiotensin-aldosterone system, which can regulate the expression of vasoconstriction, vasopressin, and aldosterone; induce angiogenesis by upregulating VEGF; and promote cell proliferation. In the circulatory system, almost all the physiological functions of Ang II are generated by stimulating the angiotensin II type 1 receptors (AT1R) 57 
LMP-1
EBV, a prototype gamma herpes virus that infects the great majority of the population worldwide, has been implicated in the pathogenesis of several human malignancies including lymphoproliferative malignancies, such as Burkitt's and Hodgkin's lymphomas, as well as epithelial tumors, such as NPC and gastric carcinoma. EBV infection in NPC is classified as latency type II, which is characterized by the expression of a limited series of latent genes, including EBV nuclear antigen-1, latent membrane protein-1 (LMP1), LMP2, and EBV early RNA 63 . Considering its oncogenic potential, LMP1
is speculated to be an essential factor in the tumorigenesis of NPC 64 . The LMP1 protein is an integral membrane protein and can be subdivided into three domains: a short intracellular N terminus, which orientates the LMP1 protein to the plasma membrane; six hydrophobic transmembrane domains, which are involved in self-aggregation and oligomerization 65 ; and an intracellular carboxyl-terminal activating region, which activates most of LMP1's signaling activities 66 and induces a variety of downstream pathological changes in cell proliferation, antiapoptosis, and metastasis 67, 68 . Therefore, Yang et al. 69 successfully obtained a phosphorothioate-modified "10-23" DNAzyme, named DZ1, which could downregulate the expression of LMP1 in NPC cells, to explore the potential use of DNAzymes for the new treatment of NPC. All results demonstrated that low expression of LMP1 in NPC cells could inhibit cell proliferation and metastasis, promote apoptosis, and enhance radiosensitivity of NPC. In addition, the potential mechanism is through the interferences of signal pathways, which are launched by LMP1 including NF-κB, AP-1, and STAT3 signal pathways 69 . Recently, Ma et al. 70 confirmed that LMP1 could regulate the expression of ATM via the NF-κB pathways, thus resulting in the change of radiosensitivity in NPC cells. Moreover, Xiao et al. 71 used a metabolomics approach to investigate EBV-modulated metabolic changes, indicating that there is a close relationship between EBV and glycolysis in NPC. Significantly, LMP1 plays a key role in the reprogramming of EBV-mediated glycolysis in NPC cells, and anti-glycolytic therapy can effectively enhance the sensitivity of LMP1-overexpressing NPC cells to radiation. Thus, antiglycolytic therapy may be a novel therapeutic strategy for NPC patients 71 .
Protein kinase CK2
Protein kinase CK2 (formerly known as casein kinase 2 or II) is a common serine/threonine protein kinase that is localized in the cytoplasmic and nuclear compartments of the cell. Protein kinase CK2 contains two regulatory (28-kDaβ) subunits and two catalytic (42-kDaα and 38-kDaα') subunits, forming the heterotetrameric configurations α2β2, αα'β2, and α'2β2. The role of CK2, which is multifunctional, in normal and abnormal cell growth, proliferation, and apoptosis has been recognized for a long time. CK2 exerts its anti-apoptotic effects through the phosphorylation of a series factors, and inhibition of CK2 can induce apoptosis and promote tumor cell proliferation 72 . Furthermore, Liu et al. 73 used RNAi technique to downregulate the protein kinase CK2α expression in NPC cells and demonstrated that CK2α knockdown significantly decreased the clonogenic activity and increased the radiosensitivity of the NPC cells. Hence, suppression of the expression of CK2 may be a potential therapeutic approach to NPC.
Bcl-2
Bcl-2 gene (also known as B-cell lymphoma/leukemia gene-2) is one of the strongest genes that have an anti-apoptotic effect and is recognized as a human longevity gene 74 . Bcl-2 gene can inhibit many apoptotic signal-induced apoptosis, promote cell survival, and disorder regulatory mechanism of apoptosis in vivo; this gene is found expressed in a variety of malignancies, such as NPC, lung cancer, and cervical cancer 75 . Previously, a study found that Bcl-2 gene played a significant role in the promotion of tumor invasion and metastasis, and its evolvement had a close relationship with the progression of NPC 76 . Other studies demonstrated that Bcl-2 and Bcl-2/bax could be used as important indicators of radiation sensitivity in treating NPC cells 77 . Furthermore, Tian et al. 78 successfully suppressed the expression of Bcl-2 protein by using RNAi technology, thus contributing to an increase of the radiosensitivity of NPC cells. All results suggested that Bcl-2 may be a potential indicator for predicting the responses of NPC cells to radiotherapy. 
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Conclusion
NPC is a common head and neck cancer. The incidence rate is higher in southern China and Southeast Asia than in Western countries. Given its high radiosensitivity, radiotherapy is considered the primary treatment for NPC. However, radiotherapy is challenging for NPC because of the radiosensitive structures that surround the nasopharynx, including the brain stem, spinal cord, pituitary-hypothalamic axis, temporal lobes, eyes, ears, and parotid glands 87 . In addition, radiotherapy often brings adverse effects, such as xerostomia and temporal lobe necrosis. Many NPCs are resistant to radiation, which brings difficulties to treatment 87 . To improve the efficacy of radiotherapy, the use of radiosensitizers combined with ionizing radiation is beneficial.
The concept of radiosensitizers was first proposed in 1958. All the chemical and biological methods that can affect the sensitivity to radiation are named radiosensitizers, including chemotherapeutic drugs and molecular targeted agents 88, 89 .
Chemotherapeutics, such as 5-fluorouracil, platinum analogs, and DNA topoisomerase I-targeting drugs, are commonly used when combined with radiotherapy and can achieve better localregional therapeutic effects 90 . Molecular targeted agents that target DNA or not are also helpful to radiation therapy, such as EGFR blockers and COX-2 inhibitors 89 . In this article, we have summarized some of the biomarkers, classified according to the main mechanisms of radiosensitization, to enhance the responsiveness of NPC cells to radiation treatment ( Table 1) .
As described above, certain useful biomarkers can be silenced in NPC radiotherapy to enhance radiosensitivity. Meanwhile, to modify the expression of unwanted molecular biomarkers, short nucleic acid-based cancer therapeutics containing short interfering RNAs, antisense oligonucleotides, DNAzymes, and ribozymes were employed 91 . In addition, some agents can be used to silence or inhibit the expression of unwanted biomarkers, including topotecan, valsartan, and analogues of curcumin.
Targeting the biomarkers to enhance the radiosensitivity of NPC is very promising and practicable. However, some problems need to be resolved. First, most of the candidate biomarkers are examined only in the molecular level studies and are not yet evaluated in large population clinical trials. Second, the mechanisms of some biomarkers leading to radiosensitization of NPC are not yet completely known. Third, whether some of the biomarkers are specific only to NPC or are common in other cancers is unclear. Hence, large cohort clinical trials are needed to verify the feasibility, availability, and safety of biomarkers to enhance the radiosensitivity of NPC cells.
